

IN THE CLAIMS:

Please cancel claims 1-3 and 9 without prejudice.

Please amend the claims as follows:

11. (Amended) The pharmaceutical composition of claim [9 or] 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

12. (Amended) The pharmaceutical composition of claim [9 or] 10, further comprising a neurotropic factor.

19. (Amended) The method of claims [15 or 16] 15-16 or 25, wherein said neurological condition is Parkinson's disease, Alzheimer's disease, Down's Syndrome, stroke, cardiac arrest, sciatic crush, spinal cord injury, injury to sensory neurons, or degenerative disease of the retina.

Please add the following claims:

24. A method of stimulating growth of neuronal cells, comprising administering an isolated multimeric Mts1 protein complex of claim 4 to said neuronal cells.

25. A method of treating a neurological condition in a subject, wherein said neurological condition is characterized by neuronal degeneration, death or injury, comprising administering to the subject a therapeutically effective amount of an isolated multimeric Mts1 protein complex of claim 4 and a pharmaceutically acceptable carrier.

REMARKS

Applicants request that the order of inventors be listed as follows: Elisabeth Marianne Bock, Vladimir Berezin and Eugene Lukanidin.